Suppr超能文献

肥胖对心房颤动发病机制和治疗选择的影响。

Impact of Obesity on Atrial Fibrillation Pathogenesis and Treatment Options.

机构信息

Institute of Cardiovascular Sciences, University of Birmingham Birmingham United Kingdom.

出版信息

J Am Heart Assoc. 2024 Jan 2;13(1):e032277. doi: 10.1161/JAHA.123.032277. Epub 2023 Dec 29.

Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia. AF increases the risk of stroke, heart failure, dementia, and hospitalization. Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. Obesity-driven structural and electrical remodeling contribute to AF via several reported mechanisms, including adiposity, inflammation, fibrosis, oxidative stress, ion channel alterations, and autonomic dysfunction. In particular, expanding epicardial adipose tissue during obesity has been suggested as a key driver of AF via paracrine signaling and direct infiltration. Weight loss has been shown to reverse these changes and reduce AF risk and recurrence after ablation. However, studies on how obesity affects pharmacologic or interventional AF treatments are limited. In this review, we discuss mechanisms by which obesity mediates AF and treatment outcomes, aiming to provide insight into obesity-drug interactions and guide personalized treatment for this patient subgroup.

摘要

心房颤动(AF)是最常见的心律失常。AF 会增加中风、心力衰竭、痴呆和住院的风险。肥胖通过相关疾病(如高血压、糖尿病和心力衰竭)直接和间接显著增加 AF 风险。肥胖驱动的结构和电重构通过几种报道的机制导致 AF,包括肥胖、炎症、纤维化、氧化应激、离子通道改变和自主神经功能障碍。特别是,肥胖期间扩张的心外膜脂肪组织通过旁分泌信号和直接浸润被认为是 AF 的关键驱动因素。已经表明体重减轻可以逆转这些变化并降低消融后的 AF 风险和复发率。然而,关于肥胖如何影响药物或介入性 AF 治疗的研究有限。在这篇综述中,我们讨论了肥胖介导 AF 和治疗结果的机制,旨在深入了解肥胖与药物相互作用,并为这一患者亚群提供个性化治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bf4/10863823/a8be5fe98f6d/JAH3-13-e032277-g003.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验